Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA. In addition, the complement inhibitor drug, EMPAVELITM (pegcetacoplan), which is the first approved complement C3 inhibitor, developed by Apellis Pharmaceuticals, has been approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria; it is believed to bring in new possibilities for the treatment of autoimmune and inflammatory disorders. Discovered in 19th century, complement system is a part of innate immune system and tissue homeostasis, which recognizes, tags and helps to eliminate various disease-causing pathogens. In addition, complement system plays a role in the physiology of a healthy organism (homeostasis) for the removal of apoptotic cells, thereby regulating cell survival. However, inadequate complement activation results in outgrowth of pathogens and suppression of complement regulators, which ultimately becomes a disease cause. As a result, complement-targeted therapeutics have been developed; they inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.
Several drug developers are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. A variety of molecules, such as biologics, gene therapies, oligonucleotides, small interfering RNAs and small molecule-based complement therapeutics are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future. Moreover, the R&D efforts in this field are also being supported by the National Institutes of Health, which have awarded grants worth USD 837 million for research efforts in this domain over the last few years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of the complement therapeutics is likely to expand. Further, with the encouraging clinical research efforts, broadening of disease focus and efforts to go beyond C5 with innovative approaches that could decrease prices and address safety concerns, the complement therapeutics market is poised to witness steady growth over the coming years.
The ‘Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the next generation complement therapeutics in the treatment of various complement-mediated diseases. The study underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain.
Our year wise projections of the current and forecasted opportunity within the next generation complement therapeutics market have further been segmented across [A] Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), [B] Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), [C] Type of Molecule (Biologics and Small Molecules), [D] Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), [E] Type of Therapy (Monotherapy and Combination Therapy), [F] Route of Administration (Intravenous, Oral and Subcutaneous), [G] Key Geographical Regions (North America, Europe and Asia-Pacific. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Several drug developers are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. A variety of molecules, such as biologics, gene therapies, oligonucleotides, small interfering RNAs and small molecule-based complement therapeutics are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future. Moreover, the R&D efforts in this field are also being supported by the National Institutes of Health, which have awarded grants worth USD 837 million for research efforts in this domain over the last few years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of the complement therapeutics is likely to expand. Further, with the encouraging clinical research efforts, broadening of disease focus and efforts to go beyond C5 with innovative approaches that could decrease prices and address safety concerns, the complement therapeutics market is poised to witness steady growth over the coming years.
Scope of the Report
The ‘Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the next generation complement therapeutics in the treatment of various complement-mediated diseases. The study underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain.
Amongst other elements, the report includes:
- A detailed review of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), type of drug, biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous), type of therapy (monotherapy and combination therapy) and dosing frequency. In addition, it includes a list of next generation complement therapeutics with special designations. Further, the chapter presents a list of players developing next generation complement therapeutics along with information on their year of establishment, company size and location of headquarters.
- Detailed profiles of key players engaged in the development of next generation complement therapeutics (shortlisted on the basis of company size). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
- An in-depth analysis of completed, ongoing and planned clinical studies of various next generation complement therapeutics, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
- A detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, which have been published during 2017-2021, based on parameters, such as year of publication, emerging focus areas, top authors, key research journals, popular indication(s) and therapeutic area(s).
- An in-depth analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, during period 2017-2021, on the basis of parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section, type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.
- An insightful analysis of the patents filed / granted for next generation complement therapeutics, between 2016- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
- An analysis of the partnerships that have been established in this domain since 2014, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, product distribution and commercialization agreement, research and development agreement, and research, development and commercialization agreement and other relevant types of deals.
- A detailed analysis of the various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.
- An analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.
Our year wise projections of the current and forecasted opportunity within the next generation complement therapeutics market have further been segmented across [A] Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), [B] Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), [C] Type of Molecule (Biologics and Small Molecules), [D] Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), [E] Type of Therapy (Monotherapy and Combination Therapy), [F] Route of Administration (Intravenous, Oral and Subcutaneous), [G] Key Geographical Regions (North America, Europe and Asia-Pacific. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the leading industry and non-industry players engaged in the development of next generation complement therapeutics?
- Which are the key drugs being developed across early and late stages of development?
- Which geographies are the most active in conducting clinical trials related to next generation complement therapeutics?
- What is the focus area of various publications related to the next generation complement therapeutics?
- Which are the leading funding institutes / centers supporting the research related to next generation complement therapeutics?
- What kind of partnership models are commonly adopted by industry stakeholders?
- Who are the key investors, active in the field of next generation complement therapeutics?
- What are the different initiatives undertaken by big pharma players for the development of next generation complement therapeutics in the recent past?
- How is the current and future market opportunity, related to next generation complement therapeutics likely to be distributed across key market segments?
Table of Contents
1. PREFACE
3. INTRODUCTION
4. NEXT GENERATION COMPLEMENT THERAPEUTICS: MARKET LANDSCAPE
5. COMPANY PROFILES
6. CLINICAL TRIAL ANALYSIS
7. PUBLICATION ANALYSIS
8. GRANT ANALYSIS
9. PATENT ANALYSIS
10. PARTNERSHIPS AND COLLABORATIONS
11. FUNDING AND INVESTMENT ANALYSIS
12. BIG PHARMA PLAYERS
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
14. EXPERT OPINION
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Achillion Pharmaceuticals (acquired by Alexion Pharmaceuticals)
- Adage Capital Management
- ADIENNE
- Adverum Biotechnologies
- AffaMed Therapeutics
- AJU IB Investment
- Akari Therapeutics
- Alexion Pharmaceuticals
- Ally Bridge
- Alnylam Pharmaceuticals
- Alsonex
- Amgen
- Amyndas Pharmaceuticals
- Annexon Biosciences
- Apellis Pharmaceuticals
- Aquilo Capital
- argenx
- Assistance Publique - Hôpitaux de Paris (AP-HP)
- AstraZeneca
- Athyrium Capital Management
- Attune Pharmaceuticals
- Bain Capital Life Sciences
- Bayer
- Beam Therapeutics
- BioCryst Pharmaceuticals
- Biogen
- BioMarin Pharmaceutical
- Bioverativ (acquired by Sanofi)
- BlackRock
- Blackstone Life Sciences (BXLS)
- Boston University Medical Campus (BUMC)
- Boxer Capital
- Bristol Myers Squibb
- Broad Institute
- Broteio Pharma
- Burrage Capital Management
- Camurus
- CANbridge Pharmaceuticals
- Catalyst Biosciences
- Center for Research on Inflammatory Diseases (CRID)
- ChemoCentryx
- China Life Private Equity Investment
- Chugai Pharmaceutical
- Cincinnati Children's Hospital Medical Center
- Clarus (acquired by Blackstone)
- Clinigen
- Clough Capital Partners
- Columbia University Health Sciences
- Complement Pharma
- Cormorant Asset Management
- Correlation Ventures
- CRG Capital Partners
- CSL Behring
- CVie Therapeutics
- DAFNA Capital Management
- Deerfield Management
- Dicerna Pharmaceuticals
- Dompé Pharmaceuticals
- Duke University
- Dyax (acquired by Shire)
- East West Bank
- Epidarex Capital
- Eventide Asset Management
- Farallon Capital Management
- Federal Ministry of Education and Research (Germany)
- Federal Ministry of Health (Germany)
- Foresite Capital
- F-Prime Capital Partners
- Frazier Life Sciences
- Future Industry Investment Fund
- Genentech
- GENERIUM
- Genzyme (a subsidiary of Sanofi)
- GlaxoSmithKline
- Halozyme Therapeutics
- Harvard College
- Hemera Biosciences
- Hercules Capital
- Hillhouse Capital
- Icahn School of Medicine at Mount Sinai (ISMMS)
- I-Mab
- InflaRx
- Innate Pharma
- Innovent Biologics
- Ionis Pharmaceuticals
- IQVIA
- ISU ABXIS
- Iveric Bio
- Janus Henderson Investors
- Johns Hopkins University
- KalVista Pharmaceuticals
- Karolinska Institutet
- Kissei Pharmaceutical
- Legend Capital
- LifeSci Venture Partners
- Lilly Asia Ventures
- Logos Capital
- Longwood Fund
- Mallinckrodt
- Massachusetts General Hospital
- MidCap Financial
- Milestone Capital Advisors
- Morningside Ventures
- MorphoSys
- MPM Capital
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (NIHCC)
- Neopharm
- New Enterprise Associates (NEA)
- NewBridge Pharmaceuticals
- Nichi-Iko Pharmaceutical
- Novartis
- Novartis Venture Fund
- NovelMed Therapeutics
- Novo
- NOXXON Pharma
- NYU Grossman School of Medicine
- Omeros
- OMERS
- OrbiMed Advisors
- Oxford Finance
- PANTHERx
- Parexel
- Paulson Investment
- Perceptive Advisors
- Pharmasyntez
- Pharming
- Ping An
- Prothix
- Qiming Venture Partners
- Quartesian
- QVT Financial
- RA Capital Management
- Ra Pharmaceuticals (acquired by UCB)
- Redmile
- Regeneron
- Regenesance
- Roche
- Rock Springs Capital
- Royalty Pharma
- RPC Pharma
- RTW Investments
- Samsung Bioepis
- Sanofi
- Satter Investment Management
- Satter Medical Technology Partners
- Sectoral Asset Management
- Selexis
- SFJ Pharmaceuticals
- Shire (acquired by Takeda)
- Silence Therapeutics
- Sobi
- Sofinnova
- Staidson Hongkong Investment
- Stanford University
- Surveyor Capital
- SV Life Sciences
- Taikang Insurance
- Takeda
- Tang Capital Management
- Tasly Biopharmaceuticals
- Temasek
- TF Capital
- Torii Pharmaceutical
- UCB
- UC San Diego
- University of California, San Francisco
- University of Cambridge
- University of Colorado
- University of Leicester
- University of Michigan
- University of North Carolina at Chapel Hill
- University of Pennsylvania
- University of Pittsburgh
- venBio Global Strategic Fund
- venBio Select
- Venrock
- Vifor Pharma
- Vivo Capital
- Washington University
- WuXi Biologics
- Xencor
- Yale University
- Zealand Pharma
Methodology
LOADING...
